Multivariate analysis identified a history of MS and a baseline BMI ≥30.5 kg/m2 as independent negative predictors of treatment response, potentially due to altered postprandial GLP-1 and PYY secretion patterns in post-MS patients (23). Here, GLP1R is linked to myeloid sarcoma.